<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034201</url>
  </required_header>
  <id_info>
    <org_study_id>119273</org_study_id>
    <secondary_id>R21DA034824-01A1</secondary_id>
    <nct_id>NCT02034201</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <brief_summary>
    <textblock>
      Methamphetamine dependence is a serious public health problem, with methamphetamine abusers&#xD;
      being at risk for significant morbidity and mortality, including HIV. To date, no medication&#xD;
      or psychotherapeutic strategy has shown robust, long-term efficacy in treating this disorder.&#xD;
      This clinical trial will examine whether lisdexamfetamine shows promise in alleviating&#xD;
      withdrawal symptoms and preventing relapse relative to placebo in recently-abstinent&#xD;
      methamphetamine dependent individuals. Findings of this study will not only shed light on&#xD;
      whether lisdexamfetamine may improve upon treatment for this disorder but also inform future&#xD;
      medication development strategies for improving treatment for drug dependence disorders.&#xD;
      Discovering efficacious limited risk interventions that show more robust, longer-term&#xD;
      outcomes would be beneficial both to the individual and society.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 19, 2016</completion_date>
  <primary_completion_date type="Actual">May 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants that relapse to methamphetamine use.</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>Lisdexamfetamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally daily through week 6 of the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine</intervention_name>
    <arm_group_label>Lisdexamfetamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age (18-65 yrs).&#xD;
&#xD;
          2. Participants must fulfill DSM-IV criteria for Methamphetamine dependence These&#xD;
             criteria will be ascertained in the following manner: the physician will determine&#xD;
             whether the individual is appropriate based on clinical assessments and the patient&#xD;
             will also need to meet criteria for methamphetamine dependence based on administration&#xD;
             of the SCID.&#xD;
&#xD;
          3. Self-reported average METH use of at least 250 mg of methamphetamine per occasion at&#xD;
             least once weekly during the preceding 3-month period.&#xD;
&#xD;
          4. A positive urine toxicology screen for methamphetamine. Participants must submit a&#xD;
             urine sample negative for drugs of abuse (opiates, benzodiazepines, cocaine and PCP)&#xD;
             other than methamphetamine or marijuana during the week prior to starting the study.&#xD;
&#xD;
          5. Women of child-bearing potential will be included provided they 1) have a negative&#xD;
             pregnancy test, 2) agree to adequate contraception (tubal ligation, hysterectomy,&#xD;
             barrier contraceptive method or oral contraceptive method) to prevent pregnancy during&#xD;
             the study and 3) are not nursing.&#xD;
&#xD;
          6. Normal blood pressure with SBP &gt;89 and &lt; 141, DBP &gt;59 and &lt; 91.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current suicidality or psychosis&#xD;
&#xD;
          2. Current cocaine dependence or opioid, alcohol, or sedative physical dependence&#xD;
&#xD;
          3. Major hepatic or cardiovascular disorder (including history of myocardial infarction,&#xD;
             cardiovascular disease, or history of or currently clinically significant ECG&#xD;
             abnormality) or unstable medical condition that contraindicates study participation&#xD;
&#xD;
          4. History of schizophrenia or bipolar type I disorder&#xD;
&#xD;
          5. Use of medications that would be expected to have major interaction with LDX including&#xD;
             psychotropics&#xD;
&#xD;
          6. Medical contraindication to receiving LDX&#xD;
&#xD;
          7. Positive drug screen for cocaine, opiates, sedatives or PCP.&#xD;
&#xD;
          8. History of Seizure disorder&#xD;
&#xD;
          9. Documented hypersensitivity to sympathomimetic amines&#xD;
&#xD;
         10. LFT &gt;3xULN&#xD;
&#xD;
         11. Pregnancy/nursing&#xD;
&#xD;
         12. Current use or past 2 weeks use of MAOi&#xD;
&#xD;
         13. History of Narrow-angle glaucoma&#xD;
&#xD;
        g.n. History of Hyperthyroidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

